Neonatal/perinatal diagnosis of hemolysis using ETCOc.
2022 AAP guidelines
Anemia
ETCOc
HDFN
Hemolytic disease of the fetus and newborn
Hyperbilirubinemia
Jaundice
Journal
Seminars in fetal & neonatal medicine
ISSN: 1878-0946
Titre abrégé: Semin Fetal Neonatal Med
Pays: Netherlands
ID NLM: 101240003
Informations de publication
Date de publication:
22 Oct 2024
22 Oct 2024
Historique:
medline:
26
10
2024
pubmed:
26
10
2024
entrez:
25
10
2024
Statut:
aheadofprint
Résumé
Hemolysis is a pathological shortening of the red blood cell lifespan. When hemolysis occurs in a neonate, hazardous hyperbilirubinemia and severe anemia could result. Hemolysis can be diagnosed, and its severity quantified, by the non-invasive measurement of carbon monoxide (CO) in exhaled breath. The point-of-care measurement is called "End-tidal CO corrected for ambient CO" (ETCOc). Herein we explain how ETCOc measurements can be used to diagnose and manage various perinatal/neonatal hemolytic disorders. We provide information regarding five clinical situations; 1) facilitating a precise diagnosis among neonates presenting with anemia or jaundice of unknown etiology, 2) monitoring fetal hemolysis with serial measurements of mothers during pregnancy, 3) measuring the duration of hemolysis in neonates with hemolytic disease, 4) measuring neonates who require phototherapy, to determine whether they have hemolytic vs. non-hemolytic jaundice, and 5) measuring all neonates in the birth hospital as part of a jaundice-detection and management program.
Identifiants
pubmed: 39455373
pii: S1744-165X(24)00029-5
doi: 10.1016/j.siny.2024.101547
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
101547Informations de copyright
Copyright © 2024 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors have no conflicting interests to declare.